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Abstract: Defects in histone methyltransferases (HMTs) are major contributing factors in neurodevelop-
mental disorders (NDDs). Heterozygous variants of SETD1A involved in histone H3 lysine 4 (H3K4)
methylation were previously identified in individuals with schizophrenia. Here, we define the clini-
cal features of the Mendelian syndrome associated with haploinsufficiency of SETD1A by investigat-
ing 15 predominantly pediatric individuals who all have de novo SETD1A variants. These individuals
present with a core set of symptoms comprising global developmental delay and/or intellectual dis-
ability, subtle facial dysmorphisms, behavioral and psychiatric problems. We examined cellular pheno-
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Defects in histone methyltransferases (HMTs) are major contributing factors in neurodevelopmental 
disorders (NDDs). Heterozygous variants of SETD1A involved in histone H3 lysine 4 (H3K4) 
methylation were previously identified in individuals with schizophrenia. Here, we define the clinical 
features of the Mendelian syndrome associated with haploinsufficiency of SETD1A by investigating 
15 predominantly pediatric individuals who all have de novo SETD1A variants. These individuals 
present with a core set of symptoms comprising global developmental delay and/or intellectual 
disability, subtle facial dysmorphisms, behavioral and psychiatric problems. We examined cellular 
phenotypes in three patient derived lymphoblastoid cell lines with three variants: p.Gly535Alafs*12, 
c.4582-2_4582delAG, and p.Tyr1499Asp. These patient cell lines displayed DNA damage repair 
defects that were comparable to previously observed RNAi-mediated depletion of SETD1A. This 
suggested that these variants, including the p.Tyr1499Asp in the catalytic SET domain, behave as 
Loss-of-Function (LoF) alleles. Previous studies demonstrated a role for SETD1A in cell cycle control 
and differentiation. However, individuals with SETD1A variants do not show major structural brain 
defects or severe microcephaly, suggesting that defective proliferation and differentiation of neural 
progenitors is unlikely the single underlying cause of the disorder. We show here that the Drosophila 
melanogaster SETD1A orthologue is required in postmitotic neurons of the fly brain for normal 
memory, suggesting a role in post development neuronal function. Together, this study defines a 
neurodevelopmental disorder caused by dominant de novo LoF variants in SETD1A and further 
supports a role for H3K4 methyltransferases in the regulation of neuronal processes underlying 
normal cognitive functioning. 
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Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of disorders including 
intellectual disability (ID) and autism spectrum disorders (ASDs)
1
. Approximately 1:200 to 1:450 
children are born with a de novo pathogenic gene variant causing a Mendelian NDD
2
. Interestingly, 
recent large-scale exome sequencing studies have shown that defects in histone methyltransferases 
(HMTs) are major contributors to ASD and ID
3, 4
. 
One of the genes involved in epigenetic modification through histone methylation is SETD1A (also 
known as KMT2F), which encodes a histone methyltransferase that mediates trimethylation of 
histone H3 on lysine 4 (H3K4me3) at promoters of active genes
5
. SETD1A methyltransferase activity 
depends on interactions with other proteins in a highly conserved complex, called ‘complex of 
proteins associated with Set1’ (COMPASS). COMPASS was originally defined in yeast
6
, and 
subsequently shown to be conserved in flies and mammals
7-9
.  
SETD1A appears to be important for multiple aspects of cell cycle regulation. For example, SETD1-
mediated H3K4me3 activates β-catenin expression, which is required for proliferation of neuronal 
progenitor cells
10
. Furthermore, SETD1A has been shown to promote cell cycle progression by 
activating the expression of micro RNAs that suppress the antiproliferative gene BTG2, which plays a 
role in the transition between the G1 and S phase of the cell cycle
11
. Finally, H3K4 methylation by 
SETD1A is crucial in maintaining genome stability, especially during DNA replication, by protecting 
newly-replicated DNA from degradation
12
. 
Heterozygous Loss-of-Function (LoF) variants of SETD1A have been identified in several human 
individuals from large schizophrenia cohort studies and have been linked to disruption of speech 
development and early-onset epilepsy
13-15
. Previously, LoF variants were also identified in a limited 
number of children with developmental delay
14
, suggesting that SETD1A variants are a common 
biological underpinning of the different aforementioned phenotypes. To provide further insight into 
the somatic and behavioral profiles, we characterised the neurodevelopmental syndrome associated 
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with SETD1A heterozygous LoF variants in this study. This is a prerequisite to develop future 
guidelines and management directed towards the vulnerability to schizophrenia or other psychiatric 
diseases. In addition, to further establish the role of SETD1A in underlying biological processes, we 
studied the effect of SETD1A variants on genome stability in patient cell lines, and investigated the 




We collected the molecular and clinical features of 15 unpublished individuals with de novo SETD1A 
variants by a collaboration facilitated by GeneMatcher
16
 in which several clinical groups 
independently identified individuals with developmental delay/intellectual disability (DD/ID) and 
related phenotypes with rare variants in SETD1A during routine diagnostic genetic testing. Clinical 
analysis of these patients was performed during regular consultations focusing on medical history, 
physical examination, and observational analysis of behavioral features. In all patients, exome 




We compared these data to available information from previously published cases with pathogenic 
SETD1A variants associated with schizophrenia and NDDs
14, 23, 24
. Ten individuals reported in these 
previous studies originate from cohorts diagnosed with schizophrenia (UK10K-Finns and Swedish 
cohorts) and six individuals originate from cohorts of individuals seen with NDDs (Deciphering 
Developmental Disorders (DDD) project, Northern Finland Intellectual Disability (NFID) study and 
Northern Finland Birth Cohorts (NFBC)). Clinical information of the previously reported individuals 
was only scarcely provided.  
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To further assess the impact of these variants on cellular SETD1A functions, we first isolated and 
generated lymphoblastoid cell lines (LCL) from 3 patients (6, 13 and 15), and from two unrelated 
controls.  
For further details on the methods used for cell culture, immunoblotting, antibodies and RNA 
isolation see Supplementary Data 1 - Methods. 
DNA Fibres 
DNA fibre analysis was carried out as described previously
12
. Briefly, cells were pulse-labelled with 
CldU and IdU (Sigma-Aldrich) for 20 min each before a 5 h exposure to 4 mM HU, and at least 200 
replication forks were analysed per experimental condition. Images were taken using a Nikon Eclipse 
Ni microscope equipped with a 60X oil lens, and were acquired and analysed using Elements v4.5 
software (Nikon). The lengths of labelled tracts were measured using ImageJ
25
 and arbitrary length 
values were converted into micrometers using the scale bars created by the microscope. 
Drosophila Stocks and Genetics 
To study the role of Set1 in postmitotic memory forming neurons of the fly brain, flies were reared 
on a standard medium (cornmeal-sugar-yeast-agar) at 25°C and 70% humidity with a 12 h: 12 h 
light/dark cycle. R14H06-Gal4 flies express Gal4 under the control of a mushroom body (MB) specific 










 were all 
generated by the Transgenic RNAi Project at Harvard University Medical School
28
 using a common 
donor strain, therefore these RNAi lines all share a common genetic background. mCherry
RNAi 
was 
used as a control in these experiments because it shares a common genetic background with all of 









 were crossed to R14H06-Gal4 for courtship conditioning and activity 
experiments, actin-Gal4 for lethality assays, and UAS-mCD8::GFP; R14H06-Gal4 for analysis of MB 





Flies were trained and tested for short-term (STM) and long-term memory (LTM) 4 days after 
eclosion using the courtship conditioning assay as previously described
29-31
. For each fly pair a 
courtship index (CI) was calculated, which is the proportion of time spent courting over 10 minutes. 
The learning Index (LI) represents the percentage of reduction in courtship behavior due to training 
and is used to directly compare memory ability between different genotypes. LI is a single value that 
is calculated from the CIs using the formula: LI= (mean-CInaïve – mean-CItrained)/ mean-CInaïve. For more 
details on the courtship conditioning procedures, see Supplementary Data 1 - Methods. 
Analysis of Activity and Sleep 
One- to five-day old flies were assayed for locomotor activity in 12 h: 12 h light/dark regimens after 
at least three days entrainment, for four full days using DAM5M monitors (Trikinetics, Waltham, 
MA). Locomotor data was collected in 1 minute bins, and a 5 minute period of inactivity was used to 
define sleep
32, 33
. Sleep parameters were analysed using pySolo and plotted
34
. Dead animals were 
excluded from analysis by a combination of automated filtering and visual inspection of locomotor 
traces. 
Analysis of Mushroom Body Morphology 
Brains from one- to five-day old day old adult male flies expressing the membrane bound UAS-
mCD8::GFP under the control of R14H06-Gal4 were dissected in 1x PBS. Dissected brains were fixed 
in 4% paraformaldehyde for 50 minutes and then washed in a PBS with 1% Triton X-100 for 5 
minutes. Brains were then mounted using Vectashield and imaged with a Zeiss LSM 710 confocal 




Patients: Molecular Phenotype 
An extensive overview of the clinical and molecular data of the patients included in this study is 
provided per individual in Supplementary Table 1. For one variant paternal genotype data was 
unavailable, therefore paternal inheritance could not be fully excluded. All other variants of the 
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SETD1A gene identified in our cohort had occurred de novo. The 15 SETD1A variants identified here 
include 5 nonsense, 6 frameshifts, 1 missense and 2 different splice site variants, of which one 
occurred in two unrelated individuals. These 14 different identified SETD1A variants were all located 
before the conserved SET domain, which is responsible for catalyzing H3K4 methylation (Figure 1).  
To gain further insight into the pathogenicity of the missense variant (Tyr1499Asp), we utilized 
several in silico prediction models. MetaDome is an online data platform that uses homologous 
domain relations and combines data from GnomAD with ClinVar to produce a ‘tolerance landscape’ 
of a gene
35, 36
. According to MetaDome the region in which the variant lies is intolerant 
(Supplementary Figure 1). In addition, several other in silico prediction tools indicated that this 
variant is pathogenic: CADD PHRED: 29.7
37
; SIFT: Deleterious, score 0
38




In each patient, the observed SETD1A variant was considered to be the most likely contributor to the 
phenotype. In general, SETD1A is depleted from truncating variants in healthy individuals (pLi=1). 
Only 2 of the 14 different variants were listed in GnomAD: c.2968C>T and c.4582-2_4582delAG (with 






. Interestingly, this latter variant, 
(c.4582-2_4582delAG) was identified in two different patients but had also been identified 
previously
14
. To determine any effects of this splice-site variant on the SETD1A transcript, RT-PCR was 
performed on cells from individual 15, amplifying a region between exon 14 and 18. The resulting 
product shows that the transcript produced in individual 15 differs from the wildtype transcript. 
Sequencing of the amplified PCR-products revealed that the variant causes an insertion of 81 base 
pairs between exon 15 and 16, showing that intron 15 is not spliced. This insertion is in frame, but 
the N-SET domain, which is important for methyltransferase activity, is interrupted (Supplementary 
Figure 2). Preventing nonsense mediated RNA decay with cyclohexamide resulted in a 50:50 ratio of 
wildtype (WT) to mutant transcript. Without cyclohexamide the WT product was higher than mutant, 
12 
 
suggesting that the mutant mRNA is partly degraded in the cell. These results suggest that this 
recurrent splice acceptor variant causes LoF by disrupting the N-SET domain of SETD1A. 
The Cellular Impact of SETD1A Variants 
Immunoblotting analyses revealed that cells from two patients, harboring the p.Gly535Alafs* and 
c.4582-2_4582delAG variants, exhibited decreased levels of SETD1A protein. The presence of the 
Tyr1499Asp variant had no effect on SETD1A protein levels (Figure 2A). Moreover, when these 
patient-derived cells were exposed to DNA damage in the form of high-dose hydroxyurea, they 
exhibited slightly elevated activation of the DNA damage response compared to WT counterparts, 
evidenced by increases in phosphorylation of CHK1 and RPA (Figure 2B). 
More strikingly, SETD1A variants were also associated with severe levels of nascent DNA degradation 
upon DNA damage, to levels comparable with depletion of SETD1A
12
. This was not evident in control 
cells, but was apparent in all 3 patient-derived cell lines examined (Figure 2C). These data suggest 
that these variants, including the Tyr1499Asp variant within the catalytic SET domain, may all lead to 
loss of SETD1A function. Moreover, given the severity of this defect, heterozygous variants in SETD1A 
mimic phenotypes that were previously observed in cell lines treated with SETD1A siRNA.  
Patients: Clinical Phenotype 
Our cohort of 15 individuals with heterozygous SETD1A variants comprised 8 females and 7 males 
whose ages varied from 34 months to 23 years (Supplementary Figure 3). The collection of clinical 
data of these individuals has allowed us to further define the clinical phenotype associated with 
SETD1A haploinsufficiency. A summary of the clinical data of the 15 patients included in this study is 
presented in Table 1. Figure 3 depicts the facial appearance of the patients for which portrait 
photographs were available. An extensive overview of the clinical features of the 15 individuals can 
be found in Supplementary Table 1. For comparison, we provide a synopsis of the clinical 
descriptions of the previously published cohort of 16 individuals with SETD1A variants
14
 in addition to 
13 
 
our clinical data (Column 17 in Supplementary Table 1). For additional detailed clinical information 
per individual, see Supplementary Data 2 - Results. 
Development  
Global developmental delay was reported in 14/15 individuals, including delayed speech and 
language development (14/14) and motor development (13/14). In 6 patients formal IQ evaluations 
have been performed, confirming intellectual disability (TIQ < 70) in 5/6 patients. In the other 
individuals, observations in educational environments indicated learning difficulties or 
developmental delay in 6/9 individuals. The level of ID or developmental delay is generally mild. 
Behavioral and Psychiatric Abnormalities 
Because of the previously reported association between schizophrenia and variants in the SETD1A 
gene
14
, we specifically looked at psychiatric and behavioral abnormalities in our patient cohort. 
Behavioral abnormalities were observed in 14/15 individuals. These consisted of aggressive behavior 
(5/14), anxiety (4/14), short attention span (4/14), autistic features (3/14), overfriendliness (3/14) 
and abnormal temper tantrums (2/14). In our cohort, 7 out of 12 patients suffered from sleep 
disturbances, including night terrors. 
There were signs (though no formal diagnoses) of a psychotic disorder in two individuals in the 
cohort. First, case 15, a 23-year-old man with the recurrent splice acceptor change (c.4582-
2_4582delAG), experienced periods with apparent negative symptoms associated with schizophrenia 
(somberness and social withdrawal), alternating with periods of euphoria. He was treated with 
aripiprazole, 10 mg daily. He also showed aggressive and addictive behavior from a young age and 
has been diagnosed with PDD-NOS (DSM-IV criteria), which is part of the autism spectrum according 
to current diagnostic criteria (DSM-V)
1
. Second, case 3, a 16-year-old female, showed symptoms that 
could be classified as visual hallucinations and imperative auditory hallucinations, as she was 
reported to “hear voices telling her to do things and see things that are not there”. This seemed to be 
transient and has not reoccurred. Because she was assessed as doing well, she so far has received 




Seizures were present in 3/15 individuals, with some very severe forms. For example, case 2 had 
myoclonic-astatic epilepsy. Drug treatment was sufficient to control seizures in case 2 and 3, but for 
case 11 hemispherectomy was required for seizure control. Hypotonia was reported in 9/15 
individuals, often manifesting during infancy and remained relatively mild. In 4/12 patients for which 
MRI has been performed, morphological abnormalities of the brain were reported including corpus 
callosum abnormalities, cerebral white matter abnormalities, T2 hyperintensities, and Chiari I 
malformation. Other reported neurological abnormalities are EEG abnormalities, encephalopathy, 
dysarthria, slight tremor, sensory processing disorder, and short-term memory deficit.  
Musculoskeletal Abnormalities 
Musculoskeletal abnormalities mainly affect the extremities (12/15) and included pes planus (6/12), 
broad/wide fingers (3/12), long fingers (2/12), and tapered fingers (2/12). Joint hypermobility was 
reported for 7/13 individuals. Other, less penetrant musculoskeletal abnormalities included 
plagiocephaly (2/15), hyperlordosis (2/15), craniosynostosis (2/15), kyphosis (1/15), pectus 
excavatum (1/15), hip dysplasia (1/15), postural instability (1/15), right sided preference (1/15), and 
congenital torticollis (1/15). 
Gastrointestinal Abnormalities  
Gastrointestinal abnormalities were present in 8/12 individuals. Feeding difficulties were reported 
for 3/8 individuals. The feeding difficulties mainly occurred and resolved during infancy. Constipation 
was observed in 3/8 individuals. Less common features included gastroesophageal reflux, frequent 
bowel movements and insatiable appetite. 
For additional clinical information on highlighted individual cases see Supplementary Data 2 - Results. 
Drosophila: Memory Phenotype 
To gain insight into the function of SETD1A in neurons, we investigated Drosophila Set1, which is an 
orthologue of human SETD1A and SETD1B. Both SETD1A and SETD1B are mutated in individuals with 
overlapping neurodevelopmental disorders
41
. The Set1 family of proteins are known to be important 
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regulators of cell proliferation and differentiation
10-12, 42, 43
. However, phenotypes that are normally 
associated with altered cell proliferation, i.e. overgrowth and cancer, are not frequently observed in 
SETD1A or SETD1B patient cohorts. To gain insight into the role of Drosophila Set1 in other aspects of 
neurobiology, we investigated terminally differentiated postmitotic neurons of the Drosophila 
mushroom body (MB), the primary learning and memory center of the fly brain.  
Since germline Set1 mutants are lethal
44
, we used the spatially restricted Gal4/UAS system
45
 to 
induce targeted RNA interference (RNAi) of Set1. Postmitotic MB neurons were targeted using the 
R14H06-Gal4 driver line, which we have characterised previously
26, 27
. R14H06-Gal4 is highly specific 
for the MB in adult and larval fly brains
46
. It is also expressed in a few cells of the ventral nerve chord, 
which appear to be chordotonal sensory neurons involved in balance and locomotion. We obtained 
three different Set1 UAS-RNAi transgenes that target different parts of the Set1 mRNA. We tested 
the RNAi potency by crossing RNAi stocks to the ubiquitous actin-Gal4 driver. As Set1 is an essential 




 did induce lethality, 
Set1
RNAi3 
did not, suggesting that the Set1
RNAi3
 line is less potent. As a control, we used an mCherry 
RNAi strain (mCherry
RNAi
) that had the same genetic background as the Set1 RNAi strains. 
We tested the effect of postmitotic Set1 knockdown on memory using the courtship conditioning 
paradigm, a classic memory assay based on naturally occurring courtship behaviors
29
. Socially naïve 
male flies court female flies vigorously, however previously mated females reject male courtship 
attempts. In the presence of normal learning and memory, male flies reduce futile courtship behavior 
in response to sexual rejection by a non-receptive mated female. In this assay, male flies are trained 
by pairing with a premated female that rejects male courtship attempts. After 1-hour of training, the 
CI was significantly reduced in the mCherry
RNAi
 control and the less potent Set1
RNAi3
 when compared 
to naïve flies of the same genotype, indicating normal short-term memory (STM) (Figure 4A, left 





indicating defective memory upon Set1 knockdown in postmitotic MB neurons. We observed similar 
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 showed a significantly reduced LI when compared to the 
control for both STM and LTM, while Set1
RNAi3
 did not (Figure 4B). Taken together, these data suggest 
that Set1 is required in postmitotic MB neurons for normal memory. 
We also assessed sleep, activity, and baseline courtship behavior in MB-specific Set1 knockdown 
flies. There was a small but significant (p= 0.03) reduction in sleep for Set1
RNAi1
, however, this 
reduction was not observed for Set1
RNAi2
 (Supplementary Figure 4A). Overall activity (Supplementary 





 when compared to the control. This suggests that courtship conditioning 
defects are not due to defects in locomotion or baseline courtship ability. It also suggests that 
memory defects likely arise from the role of Set1 in the MB cells, and not the chordotonal sensory 
neurons that are also targeted by R14H06-Gal4. Disruption of chordotonal organ function would be 
expected to cause severe defects in balance and locomotion, which clearly are not observed upon 
Set1 knockdown with R14H06-Gal4. 
R14H06-Gal4 is expressed in the larval MB as well as the adult MB. During larval and pupal 
development, postmitotic MB neurons undergo morphological changes that are required for normal 
wiring of the adult fly brain. We asked if memory defects in MB Set1 knockdown flies result from 
morphological abnormalities arising from defects in MB development. To test this, we labelled 
R14H06-Gal4 neurons by co-expression of a membrane targeted green fluorescent protein (GFP) and 
imaged whole mount adult brains using confocal microscopy. We did not observe gross 
morphological defects in larval, pupal, or adult stages in Set1 knockdown flies (Supplementary Figure 
4D). Thus, Set1 appears to be dispensable in postmitotic neurons for normal MB morphogenesis. 
Taken together with our behavior data, this suggests that Set1 is required for normal functioning of 




Characterization of a Novel Neurodevelopmental Disorder caused by SETD1A Haploinsufficiency 
The presented clinical and molecular data strongly support the conclusion that heterozygous LoF of 
human SETD1A causes a novel defined neurodevelopmental disorder. The core features associated 
with SETD1A haploinsufficiency include global developmental delay or intellectual disability, subtle 
facial dysmorphisms, and psychiatric problems. In previous studies heterozygous LoF variants in 
SETD1A were observed in individuals with schizophrenia
14
. Therefore, in this study we investigated 
the behavioral and psychiatric abnormalities that have been observed in our predominantly pediatric 
cohort. No patient had a previous diagnosis of schizophrenia, but this is expected because of the 
relatively young age of the patients. With the exception of the very rare childhood onset forms
47
, 
schizophrenia rarely manifests so early
48
. Interestingly, an adolescent and a young adult from our 
cohort (age 16 years and 23 years) showed signs that could be linked with schizophrenia or bipolar 
disorder, though they had no formal psychiatric diagnosis. Combined with the previous reports, this 
indicates that the germline SETD1A variants might predispose individuals to severe neuropsychiatric 
pathologies later in life. Therefore, this patient group should be carefully monitored for suggestive 
psychiatric symptoms.  
It is notable that in humans all six H3K4 methyltransferases, SETD1A/B, KMT2A/B, and KMT2C/D have 
been implicated in neurodevelopmental disorders, though it is also clear that all KMT2 members 
have distinct molecular functions
30, 41, 49-51
. However, there is an interesting overlap between these 
chromatin modulating genes and their respective phenotypes (with developmental delay/intellectual 
disability at its core), based on their shared underlying disease mechanisms
52
. 
SETD1A Mutational Mechanisms and Cellular Phenotypes  
In the 15 patients investigated in this study we identified 14 different SETD1A variants. The majority 
of these were LoF nonsense or frameshift variants, however a twice recurrent splice-site variant and 
a missense variant were also identified in the catalytic SET domain, which is required for 
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methyltransferase activity. Previously, SETD1A-mediated H3K4 methylation was shown to be 
important for protecting against DNA damage at stalled replication forks
12
. We used this cellular 
phenotype as an output to test the functional effects of clinical SETD1A variants in three patient 
derived lymphoblastoid cell lines. Interestingly, cell lines with heterozygous LoF alleles 
(p.Gly535Alafs*12, and c.4582-2_4582delAG) showed high levels of nascent DNA degradation, at a 
level of severity that was similar to that observed in cell lines treated with SETD1A siRNA
12
. 
Moreover, cells with the heterozygous missense variant (p.Tyr1499Asp) also showed a similar 
phenotype, thus supporting the pathogenicity of this variant. Taken together, these results suggest 
that SETD1A-associated clinical features likely result from partial loss of SETD1A methyltransferase 
activity.    
In two unrelated patients we found the same de novo two base pair (bp) deletion (c.4582-2_4582-
1delAG) at the splice acceptor of exon 16. The Human Splicing Finder (version 3.1) predicts that this 
two bp alteration of the acceptor splice site of exon 16 results in exon skipping
53
. Interestingly, in 
non-pathogenic situations the overall expression of exon 16 is the highest compared to the other 
exons of the gene in different tissues
54
 (Supplementary Figure 5). This suggests a significant role for 
this particular exon for the functionality of the N-SET domain, which is partly encoded by this exon. 
Our RNA analyses surprisingly revealed that exon skipping did not occur, but the two bp deletion 
rather resulted in retention of intron 15. In the three other studies describing patients with variants 
in SETD1A, the exact same variant was found in 7 out of the total of 16 patients
14, 23, 24
. In addition, 
this variant occurs at a frequency of 8.071e
-6
 in the GnomAD database
40
. Authors from the previous 
studies did not speculate on this seemingly unlikely recurrence of the two bp deletion
14, 24
. However, 
it raises questions on the frequency and etiology of occurrence of this variant. It is possible that the 
mutation rate in this genomic area, or specifically around these two base pairs, is relatively high. This 
may be due to the surrounding sequence homology or the epigenetic state of the DNA, which in turn 
may allow this deletion to occur. Another explanation might be ascertainment bias, due to the 
possibility that the specific variant gives rise to ID and/or schizophrenia. Whereas other SETD1A 
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variants might also be causative for other phenotypes and therefore would not be included in studies 
focusing on ID or schizophrenia. In addition, it might be that the c.4582-2_4582-1delAG variant is a 
so-called selfish mutation. Certain DNA variants that can occur over time in spermatogonial cells can 
lead to clonal expansion (such as the c.755C>G variant in the FGFR2 gene in the case of Apert 
syndrome). This can culminate to the passing of that certain variant from father to child, leading to a 
higher prevalence in the patient group. Typically these variants are ‘Gain of Function’ (GoF)
55, 56
, so in 
our cohort this does not seem to be the case.  
The Drosophila SETD1A Orthologue is required in Postmitotic Neurons for Memory 
SETD1A and other COMPASS components have been implicated in the regulation of cell proliferation 
and differentiation. However, there is little evidence that these processes solely underlie the clinical 
features that we describe in SETD1A haploinsufficiency, as the cognitive deficits and facial 
dysmorphisms reported in our cohort are mild. Defects in proliferation or differentiation of neural 
progenitors might have more dramatic effects on structure and function of the brain, and cause 
profound cognitive deficits or lethality. In line with this, we identified a role for Drosophila Set1 in the 
regulation of memory formation in postmitotic neurons. This finding is consistent with studies 
demonstrating a role for different histone modifications in the epigenetic regulation of memory
57
. 
For example, H3K4me3 is dynamically regulated in the rodent hippocampus during memory 
formation and Setd1a
+/-




. Several other H3K4 
methyltransferases have also been implicated in memory, including mouse Kmt2a/Kmt2b and 
Drosophila trr
30, 49, 60
. Thus, our findings on SETD1A and Drosophila Set1 support a growing body of 
literature highlighting the conserved role of H3K4 methylation in regulating the function of adult 
neurons post development.  
The specific role of H3K4 methylation in memory formation is not known. Set1-related proteins 
might regulate several different aspects of postmitotic neuronal biology that could all impact 
memory. For example, we have shown here that patient cell lines have elevated damage in nascent 
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DNA. Terminally differentiated neurons are often exposed to DNA damage and an efficient response 
is critical, as these neurons are not easily replaced. Additionally, the Set1 protein family might be 
important for maintaining the cell-type specific gene expression programs that would be critical for 
normal functioning of memory neurons. Set1-related proteins might also be required for induction of 
learning-induced gene expression changes that are known to be required for long-term memory 
formation.  
Despite the lack of a precise pathogenetic mechanism, the finding that Set1 regulates memory post 
development could have implications for therapies. Further understanding of SETD1A function in the 
postnatal brain could open up possibilities for therapy that would not be possible if pathogenic 
mechanisms occurred entirely during the prenatal stages of development. 
Compliance with ethical standards 
All procedures performed in studies involving human participants were in accordance with the 
ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.  
Informed consent was obtained from all individual participants included in the study as part of the 
diagnostic workflow. Additional informed consent was obtained from all individual participants for 
whom identifying information is included in this article. 
Acknowledgements 
We are grateful to all individuals and their parents for participating in this study.  
This work was supported by the Netherlands Organization for Health Research and Development 
(ZonMw grant 91718310) to T.K., ERA-NET NEURON-102 SYNSCHIZ (grant 013-17-003 4538) to D.S., 
Canadian Institutes of Health Research, Canadian Foundation for Innovation, and the Canada 
Research Chairs Program to J.M.K., MRC Career Development Fellowship (MR/P009085/1) and a 
University of Birmingham Fellowship to M.R.H. 
21 
 
We thank the Bloomington Drosophila Stock Center at Indiana University for providing all Drosophila 
strains used in this study. 
Sequencing and analysis for patient 2 were provided by the Broad Institute of MIT and Harvard 
Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome 
Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant 
UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. 
Conflict of interest 
All contributors have read and approved the submission to the journal.  
M.T. Cho and K. McWalter are employees of GeneDx. We are not aware of any other conflict of 
interest. 
Supplementary information is available at MP’s website. 
References 
1. Association AP. Diagnostic and statistical manual of mental disorders. 5th edn. American 
Psychiatric Publishing: Arlington, VA, 2013. 
 
2. Beckwith EJ, Geissmann Q, French AS, Gilestro GF. Regulation of sleep homeostasis by sexual 
arousal. eLife 2017; 6. 
 
3. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE et al. Synaptic, 
transcriptional and chromatin genes disrupted in autism. Nature 2014; 515(7526): 209-215. 
 
4. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D et al. The contribution of de 
novo coding mutations to autism spectrum disorder. Nature 2014; 515(7526): 216-221. 
 
5. Lee JH, Skalnik DG. Wdr82 is a C-terminal domain-binding protein that recruits the Setd1A 
Histone H3-Lys4 methyltransferase complex to transcription start sites of transcribed human 
genes. Molecular and cellular biology 2008; 28(2): 609-618. 
 
6. Miller T, Krogan NJ, Dover J, Erdjument-Bromage H, Tempst P, Johnston M et al. COMPASS: a 
complex of proteins associated with a trithorax-related SET domain protein. Proceedings of 





7. Mohan M, Herz HM, Smith ER, Zhang Y, Jackson J, Washburn MP et al. The COMPASS family 
of H3K4 methylases in Drosophila. Molecular and cellular biology 2011; 31(21): 4310-4318. 
 
8. Takahashi YH, Westfield GH, Oleskie AN, Trievel RC, Shilatifard A, Skiniotis G. Structural 
analysis of the core COMPASS family of histone H3K4 methylases from yeast to human. 
Proceedings of the National Academy of Sciences of the United States of America 2011; 
108(51): 20526-20531. 
 
9. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in 
development and disease pathogenesis. Annual review of biochemistry 2012; 81: 65-95. 
 
10. Li Y, Jiao J. Histone chaperone HIRA regulates neural progenitor cell proliferation and 
neurogenesis via beta-catenin. The Journal of cell biology 2017; 216(7): 1975-1992. 
 
11. Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R et al. SETD1A modulates cell cycle 
progression through a miRNA network that regulates p53 target genes. Nat Commun 2015; 6: 
8257. 
 
12. Higgs MR, Sato K, Reynolds JJ, Begum S, Bayley R, Goula A et al. Histone Methylation by 
SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2. 
Molecular cell 2018; 71(1): 25-41.e26. 
 
13. Eising E, Carrion-Castillo A, Vino A, Strand EA, Jakielski KJ, Scerri TS et al. A set of regulatory 
genes co-expressed in embryonic human brain is implicated in disrupted speech 
development. Molecular psychiatry 2018. 
 
14. Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J et al. Rare loss-of-function variants 
in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 
2016; 19(4): 571-577. 
 
15. Yu X, Yang L, Li J, Li W, Li D, Wang R et al. De Novo and Inherited SETD1A Variants in Early-
onset Epilepsy. Neuroscience bulletin 2019. 
 
16. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting 
investigators with an interest in the same gene. Human mutation 2015; 36(10): 928-930. 
 
17. Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, Mensenkamp AR et al. A post-
hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis 
of heterogeneous diseases. Human mutation 2013; 34(12): 1721-1726. 
 
18. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F et al. Clinical application of 
whole-exome sequencing across clinical indications. Genetics in medicine : official journal of 




19. Boonsawat P, Joset P, Steindl K, Oneda B, Gogoll L, Azzarello-Burri S et al. Elucidation of the 
phenotypic spectrum and genetic landscape in primary and secondary microcephaly. 
Genetics in medicine : official journal of the American College of Medical Genetics 2019. 
 
20. Lessel D, Gehbauer C, Bramswig NC, Schluth-Bolard C, Venkataramanappa S, van Gassen KLI 
et al. BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced 
type 2 innate lymphoid cells. Brain : a journal of neurology 2018; 141(8): 2299-2311. 
 
21. Gudbjartsson DF, Helgason H, Gudjonsson SA, Zink F, Oddson A, Gylfason A et al. Large-scale 
whole-genome sequencing of the Icelandic population. Nature genetics 2015; 47(5): 435-444. 
 
22. Weiss K, Terhal PA, Cohen L, Bruccoleri M, Irving M, Martinez AF et al. De Novo Mutations in 
CHD4, an ATP-Dependent Chromatin Remodeler Gene, Cause an Intellectual Disability 
Syndrome with Distinctive Dysmorphisms. American journal of human genetics 2016; 99(4): 
934-941. 
 
23. Takata A, Xu B, Ionita-Laza I, Roos JL, Gogos JA, Karayiorgou M. Loss-of-function variants in 
schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron 2014; 82(4): 773-
780. 
 
24. Guipponi MS, FA; Setola, V; Gehrig, C; Rotharmel, M;. Exome Sequencing in 53 Sporadic 
Cases of Schizophrenia Identifies 18 Putative Candidate Genes 2014. 
 
25. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat 
Methods 2012; 9(7): 671-675. 
 
26. Jenett A, Rubin GM, Ngo TT, Shepherd D, Murphy C, Dionne H et al. A GAL4-driver line 
resource for Drosophila neurobiology. Cell reports 2012; 2(4): 991-1001. 
 
27. Jones SG, Nixon KCJ, Chubak MC, Kramer JM. Mushroom Body Specific Transcriptome 
Analysis Reveals Dynamic Regulation of Learning and Memory Genes After Acquisition of 
Long-Term Courtship Memory in Drosophila. G3 (Bethesda, Md) 2018; 8(11): 3433-3446. 
 
28. Perkins LA, Holderbaum L, Tao R, Hu Y, Sopko R, McCall K et al. The Transgenic RNAi Project 
at Harvard Medical School: Resources and Validation. Genetics 2015; 201(3): 843-852. 
 
29. Siegel RW, Hall JC. Conditioned responses in courtship behavior of normal and mutant 
Drosophila. Proceedings of the National Academy of Sciences of the United States of America 




30. Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S et al. 
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in 
intellectual disability and autism spectrum disorder. PLoS genetics 2017; 13(10): e1006864. 
 
31. Koemans TS, Oppitz C, Donders RAT, van Bokhoven H, Schenck A, Keleman K et al. Drosophila 
Courtship Conditioning As a Measure of Learning and Memory. Journal of visualized 
experiments : JoVE 2017; (124). 
 
32. Shaw PJ, Cirelli C, Greenspan RJ, Tononi G. Correlates of sleep and waking in Drosophila 
melanogaster. Science (New York, NY) 2000; 287(5459): 1834-1837. 
 
33. Huber R, Hill SL, Holladay C, Biesiadecki M, Tononi G, Cirelli C. Sleep homeostasis in 
Drosophila melanogaster. Sleep 2004; 27(4): 628-639. 
 
34. Gilestro GF, Cirelli C. pySolo: a complete suite for sleep analysis in Drosophila. Bioinformatics 
(Oxford, England) 2009; 25(11): 1466-1467. 
 
35. Bock I, Nemeth K, Pentelenyi K, Balicza P, Balazs A, Molnar MJ et al. Targeted next generation 
sequencing of a panel of autism-related genes identifies an EHMT1 mutation in a Kleefstra 
syndrome patient with autism and normal intellectual performance. Gene 2016; 595(2): 131-
141. 
 
36. Wiel L, Venselaar H, Veltman JA, Vriend G, Gilissen C. Aggregation of population-based 
genetic variation over protein domain homologues and its potential use in genetic 
diagnostics. Human mutation 2017; 38(11): 1454-1463. 
 
37. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the 
deleteriousness of variants throughout the human genome. Nucleic acids research 2019; 
47(D1): D886-d894. 
 
38. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of 
amino acid substitutions on proteins. Nucleic acids research 2012; 40(Web Server issue): 
W452-457. 
 
39. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and 
server for predicting damaging missense mutations. Nature methods 2010; 7(4): 248-249. 
 
40. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T et al. Analysis of protein-
coding genetic variation in 60,706 humans. Nature 2016; 536(7616): 285-291. 
 
41. Hiraide T, Nakashima M, Yamoto K, Fukuda T, Kato M, Ikeda H et al. De novo variants in 





42. Blobel GA, Kadauke S, Wang E, Lau AW, Zuber J, Chou MM et al. A reconfigured pattern of 
MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation 
following mitotic exit. Molecular cell 2009; 36(6): 970-983. 
 
43. Petruk S, Sedkov Y, Johnston DM, Hodgson JW, Black KL, Kovermann SK et al. TrxG and PcG 
proteins but not methylated histones remain associated with DNA through replication. Cell 
2012; 150(5): 922-933. 
 
44. Hallson G, Hollebakken RE, Li T, Syrzycka M, Kim I, Cotsworth S et al. dSet1 is the main H3K4 
di- and tri-methyltransferase throughout Drosophila development. Genetics 2012; 190(1): 
91-100. 
 
45. Brand AH, Manoukian AS, Perrimon N. Ectopic expression in Drosophila. Methods in cell 
biology 1994; 44: 635-654. 
 
46. Chubak MC, Nixon KCJ, Stone MH, Raun N, Rice SL, Sarikahya M et al. Individual components 
of the SWI/SNF chromatin remodelling complex have distinct roles in memory neurons of the 
Drosophila mushroom body. Dis Model Mech 2019; 12(3). 
 
47. Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset 
schizophrenia spectrum disorders. Child and adolescent psychiatric clinics of North America 
2013; 22(4): 539-555. 
 
48. Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J 
Psychiatry 2009; 195(4): 286-293. 
 
49. Kerimoglu C, Sakib MS, Jain G, Benito E, Burkhardt S, Capece V et al. KMT2A and KMT2B 
Mediate Memory Function by Affecting Distinct Genomic Regions. Cell reports 2017; 20(3): 
538-548. 
 
50. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI et al. Exome 
sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nature genetics 2010; 
42(9): 790-793. 
 
51. Faundes V, Newman WG, Bernardini L, Canham N, Clayton-Smith J, Dallapiccola B et al. 
Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental 
Disorders. American journal of human genetics 2018; 102(1): 175-187. 
 
52. McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y et al. De novo mutations in 
schizophrenia implicate chromatin remodeling and support a genetic overlap with autism 




53. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing 
Finder: an online bioinformatics tool to predict splicing signals. Nucleic acids research 2009; 
37(9): e67. 
 
54. Varga E, Nemes C, Tancos Z, Bock I, Berzsenyi S, Levay G et al. Establishment of EHMT1 
mutant induced pluripotent stem cell (iPSC) line from a 11-year-old Kleefstra syndrome (KS) 
patient with autism and normal intellectual performance. Stem cell research 2016; 17(3): 
531-533. 
 
55. Goriely A, McGrath JJ, Hultman CM, Wilkie AO, Malaspina D. "Selfish spermatogonial 
selection": a novel mechanism for the association between advanced paternal age and 
neurodevelopmental disorders. The American journal of psychiatry 2013; 170(6): 599-608. 
 
56. Goriely A, Wilkie AO. Paternal age effect mutations and selfish spermatogonial selection: 
causes and consequences for human disease. American journal of human genetics 2012; 
90(2): 175-200. 
 
57. Kim S, Kaang BK. Epigenetic regulation and chromatin remodeling in learning and memory. 
Experimental & molecular medicine 2017; 49(1): e281. 
 
58. Mukai J, Cannavo E, Crabtree GW, Sun Z, Diamantopoulou A, Thakur P et al. Recapitulation 
and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice. Neuron 2019. 
 
59. Gupta S, Kim SY, Artis S, Molfese DL, Schumacher A, Sweatt JD et al. Histone methylation 
regulates memory formation. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 2010; 30(10): 3589-3599. 
 
60. Kerimoglu C, Agis-Balboa RC, Kranz A, Stilling R, Bahari-Javan S, Benito-Garagorri E et al. 
Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 2013; 33(8): 
3452-3464. 
 
61. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D et al. InterPro: the 








Figure 1  
The genomic position and coding consequences of 14 different SETD1A variants. All variants are 
located 5’ to the conserved SET domain, which is responsible for catalyzing methylation. The splice 
acceptor variant at exon 16 (c.4582-2delAG) was identified in two unrelated patients. Mapping of the 
different domains (IPR024657, IPR001214, IPR000504 and IPR003616) on the gene was done 





(A) Whole cell extracts (WCE) from the indicated patient-derived lymphoblastoid cell lines (LCL) were 
analysed by immunoblotting using the denoted antibodies. Data is derived from the untreated 
samples in (B). 
(B) Patient-derived LCL were exposed to 2 mM HU for 24 h, WCE prepared and analysed by 
immunoblotting using the denoted antibodies. Data is representative of n=2 independent 
experiments. * Denotes a non-specific band. 
(C) Patient-derived LCL were sequentially pulsed for 20 min each with CldU and IdU, and exposed to 4 
mM HU for 5 h (as in the schema). DNA was visualised with antibodies to CldU and IdU, and tract 
length was calculated. Plots denote the average ratios of IdU:CldU label length from three 
independent experiments. Red lines indicate mean ratios. Data represents pooled values from n=3 
experiments, representative images are shown. 
 
Figure 3 
Clinical portrait photographs of patients with a SETD1A pathogenic variant. The most prominent 
facial features to be observed are high forehead (7/15), low-set ears (4/15), microtia (3/15), 
downslanted palpebral fissures (6/15), epicanthus (7/15), deeply set eyes (4/15), hypertelorism 
(4/15), wide nose (6/15), anteverted nares (4/15), full cheeks (2/15), everted/tented upper lip 
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vermillion (8/15), wide mouth (4/15) and widely spaced teeth (3/15).  
 
Figure 4  
Mushroom body specific knockdown of Set1 causes defects in short- and long-term memory.  
(A) Courtship memory was measured in control flies and in flies that express Set1 RNAi constructs 
localized to the mushroom body by the R14H06-Gal4 driver. Three Set1 RNAi lines were compared to 
the mCherry
RNAi
 control, which is present in the same genetic background as the Set1 RNAi lines. 
Boxplots show the distribution of Courtship Indices (CIs) for naïve (N) and trained (T) flies of control 
and Set1 RNAi lines. (*) And (****) indicate a significant reduction in CI trained flies compared to 
naïve (Mann-Whitney Test; p<0.05 and p<0.0001, respectively). + Indicates the mean. N is indicated 
along x-axis.  
(B) Bar graphs showing the Learning indices (LI), which are single values that are derived from the 





, but not Set1
RNAi3
. ** p<0.01, **** p<0.0001, randomization test, 




Summary of clinical features found in the cohort of 15 individuals with SETD1A variants.* 
* More extensive clinical information per individual is provided in Supplementary Table 1. 
As information on the different features was not always applicable or known for each patient, 







Table 1. Summary of clinical features found in the cohort of 15 individuals with SETD1A variants.*
Frequency Precentage
Growth





Speech delay 14/14 100%
Motor delay 13/14 93%
Behavioural/psychiatric abnormalities 14/15 93%
Sleep disturbance 7/12 58%
Aggressive behavior 5/14 36%
Short attention span 5/14 36%
Anxiety 4/14 29%




Structural brain abnormalities on MRI 4/12 33%
Musculoskeletal abnormalities
Joint hypermobility 7/13 54%
Craniosynostosis 2/15 13%
Gastrointestinal abnormalities 8/12 67%
Feeding difficulties 3/8 38%
Constipation 3/8 38%
Craniofacial dysmorphisms 15/15 100%
Other
Recurrent infections 7/15 47%
Skin abnormalities 4/15 27%
Visual impairment 6/15 40%
Hearing impairment 2/15 13%
* More extensive clinical information per individual is provided in Supplementary Table 1. As information o
n the different features was not always applicable or known for each patient, the denominator in the 'F
Frequency' column is different for different clinical characteristics.
